Z. N. Nikiphorova

Z. N. Nikiphorova

Auto-generated profile, based on publicly available information

Z. N. Nikiphorova

Russian State Center for Animal Feed and Drug Standardization and Quality

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
Verified
Journal Article
Closed access
PDF file
ZNZ. N. Nikiforova
Z. N. Nikiforova
MTM. A. Taipov
M. A. Taipov
IKI. A. Kudryavtsev
I. A. Kudryavtsev
VSV. E. Shevchenko
V. E. Shevchenko
Breast cancer (BC) is the most common form of cancer, leading to high mortality rates among women worldwide. In this study we have analyzed mRNA expression of 15-hydroxy-prostaglandin-dehydrogenases (15-HPGD), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) and miRNAs (miR-21, miR-155) in three cell lines of estrogen-positive human breast carcinomas (MCF-7, BT-474, ZR-75-1). Results of three independent experiments have demonstrated significantly higher levels of COX-2 and COX-1 mRNAs in the cell line ZR-75-1 cells than in MCF-7 and BT-474 cells. mRNA levels of total 15-HPGD and functional-15-HPGD were lower in BT-474 than in MCF-7 and in ZR-75-1 cells. Synthesis of the 15-HPGD enzyme in BT-474 cells was blocked at the level of nuclear processing of an immature pre-mRNA. High expression of miR-21 was detected in all the tumor cell lines (MCF-7, ZR-75-1 and BT-474). In the breast cancer cell lines, the expression level of miR-155 was significantly lower than that of miR-21. Correlations have been found between dysregulation of miR-21, miR-155 and mRNA levels of 15-HPGD, COX-1, COX-2. The results obtained in this study showed that miR-21 and miR-155 regulate activity of several genes in the tumor cell and on some genes they exhibited a cumulative effect. Based on these results, we concluded that the miR-21 and miR-155 inhibit activity of the tumor suppressor gene 15-HPGD and induce a potential oncogene COX-2, which contributes to malignancy and metastasis of breast cancer cells.

15 May 2016 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
ZNZ. N. Nikiforova
Z. N. Nikiforova
IKI. A. Kudryavtsev
I. A. Kudryavtsev
NAN. E. Arnotskaya
N. E. Arnotskaya
IBI. S. Bryukhovetskiy
I. S. Bryukhovetskiy
VSV. E. Shevchenko
V. E. Shevchenko
Glioblastoma multiforme, a World Health Organization grade IV malignant glioma, is the most common and lethal primary brain tumor with the median survival of approximately 15–25 months after treatment. Glioblastoma multiforme has been shown to be resistant to radiotherapy and chemotherapy and invariably recurs following surgical resection and chemoradiation. The characteristics of this tumor are exemplified by heterogeneous cell population with diverse biologic properties and genetic changes, the ability to form cancer stem cells (CSC) and divided into four molecular subtypes – proneural, neural, classical and mesenchymal. Despite some success, the mechanisms leading to the formation of the most malignant tumor subtype are unclear. The aim of this review was a synthesis of modern information about the role and biological characteristics of tumor stem cells in tumor progression and the pathogenesis of glioblastoma multiforme. CSCs reside in niches, which are anatomically distinct regions within the tumor microenvironment. These niches maintain the principle properties of CSCs, preserve their phenotypic plasticity, adhesion, survival, resistance to standard cancer treatment and metastatic potential. The presence of aberrant signaling pathways (Notch, Hedgehog-Gli, Wnt/β-catenin, TGF-β/SMAD, PI3K/Akt/mTOR), both in the tumor and in the population of CSC, the dysregulation of microRNAs (miR-21, miR-128, miR-326, miR-34a), influence of epithelial-to-mesenchymal transition explains the availability of typical biological characteristics of the CSC. One needs to consider the influence of the therapy on normal stem cells in the development of drugs directed against the CSC. Regulatory mechanisms and markers found over the last decade can be used as the basis for creation of the new drugs with targeted action in the treatment of glioblastoma multiforme.

1 January 2005
Verified
Journal Article
Closed access
ZNZ N Nikiforova
Z N Nikiforova
VSV E Shevchenko
V E Shevchenko
ZVZ V Volkova
Z V Volkova
OGO V Gudoshnikova
O V Gudoshnikova
NDN V Dmitrieva
N V Dmitrieva
NAN E Arnotskaia
N E Arnotskaia

15 January 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VSV. E. Shevchenko
V. E. Shevchenko
ABA. S. Bryukhovetskiy
A. S. Bryukhovetskiy
MFMichael Filatov
Michael Filatov
VBV. S. Burdakov
V. S. Burdakov
ZNZ. N. Nikiforova
Z. N. Nikiforova
ЮВЮ. Д. Василец
Ю. Д. Василец
Background. Multiple myeloma (MM) is a hematologic malignancy of plasma cells. The microenvironment plays a key role in MM cell survival and drug resistance through release of soluble factors, expression of adhesion molecules and release of exosomes (EXs). The role that EXs, released by MM cells have in cell-to-cell communication and signaling in the bone marrow is currently unknown. EXs as a source of markers for MM diagnostics are also not studied.Objective: to use proteomic profiling of EXs as a tool to identify circulating tumor associated markers in MM patients.Results. The proteome composition of EXs obtained from plasma of patients with MM and multiple sclerosis was studied for the first time. nano-HPLC–MS/MS analysis identified a total of 332 proteins in the EXs of both groups of patients and determined the proximity of their qualitative composition. For the first time, 12 differentially expressed proteins were detected, the levels of which were significantly increased in EXs from patients with MM. This allowed us to consider them as potential markers of the disease.Conclusion. Proteomic analysis of EXs obtained from plasma of patients with MM is an important method for finding disease markers.

15 September 2022 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VSV. E. Shevchenko
V. E. Shevchenko
ZNZ. N. Nikiforova
Z. N. Nikiforova
TKT. I. Kushnir
T. I. Kushnir
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
NAN. E. Arnotskaya
N. E. Arnotskaya
Introduction. Treatment of glioblastoma multiforme remains little effective due to the rapidly developing recurrence of the tumor, due to its high tumorigenic potential, resistance to chemoradiation therapy and increased dissemination of glioma stem cells. The identification of potential therapeutic targets, which make it possible to more effectively destroy glioma stem cells, becomes topical. In this regard, the study of ferroptosis (FP), which can cause the death of tumor cells with a highly malignant phenotype, is of great importance. However, FP and its regulatory pathways in the GSC are not fully understood. At present, it is also not clear how FP differs for glioma stem cells and glioblastoma differentiated cells.Aim. To study the expression of ferroptosis signaling cascade determinants in CD133+ glioma stem cells and CD133- glioblastoma differentiated cells using high resolution proteomic mass spectrometry.Materials and methods. High-resolution proteomic mass spectrometry, cell technologies.Results. In total, 1970 proteins were identified, 15 of which are associated with ferroptosis and are present in both cell populations. Upregulation of 12 FP determinants (ACSL1, ACSL3, COPZ1, FTH1, FTL, GPX1, GPX4, PCBP1, SLC3A2, TFRC, VDAC1, VDAC2) was found in CD133+ glioblastoma stem cells compared to CD133- differential glioblastoma cells, 10 of which were more than 2-fold overexpressed.Conclusion. Important regularities have been established in the expression of ferroptosis determinants and proteins controlling this process in glioma stem cells, which can be used in the development of new approaches to the detection of potential targets for the therapy of glioblastoma multiforme.

1 November 2013 in European Urology Supplements
Verified
Journal Article
Closed access
VCV. Chernyaev
V. Chernyaev
VMV.B. Matveev
V.B. Matveev
MVM.I. Volkova
M.I. Volkova
ZNZ. Nikiforova
Z. Nikiforova
VSV.E. Shevchenko
V.E. Shevchenko